Posted inGastroenterology news Pediatrics
FDA Approves Golimumab (Simponi) for Pediatric Ulcerative Colitis: A New Therapeutic Option
The FDA has approved golimumab (Simponi) for treating moderately to severely active ulcerative colitis in children weighing at least 15 kg, based on the PURSUIT 2 phase 3 study demonstrating significant clinical remission and safety.